Understanding Doxorubicin Resistance in Triple-Negative Breast Cancer
Author Information
Author(s): Vishnubalaji Radhakrishnan, Alajez Nehad M.
Primary Institution: Qatar Biomedical Research Institute (QBRI)
Hypothesis
This study aimed to explore the molecular changes associated with doxorubicin resistance and identify potential therapeutic targets to overcome this resistance.
Conclusion
The study suggests new treatment approaches that could target survival strategies in doxorubicin-resistant triple-negative breast cancer to improve chemotherapy effectiveness.
Supporting Evidence
- Doxorubicin-resistant cells showed reduced proliferation and migration but enhanced tolerance to doxorubicin.
- RNA-Seq analysis revealed upregulation of cytokine signaling and stress-response pathways in resistant cells.
- A 27-gene signature associated with doxorubicin resistance was linked to worse clinical outcomes.
Takeaway
Some breast cancer cells can become sleepy and stop growing when treated with a medicine called doxorubicin, making it hard to kill them. This study looks for ways to wake them up and make the medicine work better.
Methodology
Doxorubicin-resistant TNBC models were generated, followed by RNA sequencing and various functional assays to assess cellular behavior.
Statistical Information
P-Value
<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website